Clinical Trials

Primary Breast Cancer

NCT04115410 2020-05-28

PD-1 Immune Checkpoint Inhibitors and Immune-Related Adverse Events: a Cohort Study

Unknown

4,724 enrolled

Carcinoma, Non-Small-Cell Lung

NCT04307147 2020-03-13

NX in Luminal B Breast Cancer Patients After Neoadjuvant Chemotherapy

316 enrolled

Breast Neoplasms

NCT04302441 2020-03-10

A Study to Evaluate Vinorelbine Plus Capecitabine Combined With Trastuzumab for HER2 Positive Patients Following Neoadjuvant Chemotherapy

550 enrolled

Breast Neoplasms

NCT04208854 2019-12-26

VINORELBINA

Unknown

40 enrolled

Locally Advanced/ Metastatic NSCLC

NCT03656094 2019-12-09

Chemotherapy With Pembrolizumab Continuation After Progression to PD-1/L1 Inhibitors

98 enrolled

Non-small Cell Lung Cancer Metastatic

NCT04143906 2019-10-30

Vinorelbine/Carboplatin Versus Gemcitabine/Carboplatin in Metastatic Breast Cancer

Breast Neoplasms

NCT04021992 2019-08-06

GVD±R Regimen for ASCT-eligible Patients With Refractory/Relapsed DLBCL

48 enrolled

Lymphoid

Lymphoma, Large B-Cell, Diffuse

NCT03997539 2019-06-25

A Study of Pyrotinib Plus Vinorelbine in Comparison With Treatment of Physician's Choice in Participants With HER2-positive Locally Advanced or Metastatic Breast Cancer

256 enrolled

Breast Neoplasms

NCT03932526 2019-04-30

Combined Use of Apatinib Mesylate and Vinorelbine Versus Single Use of Vinorelbine in Triple-negative Breast Cancer

184 enrolled

Triple Negative Breast Neoplasms

NCT03925233 2019-04-24

Breast Cancer Treatment Based on Organ-like Culture

Unknown

300 enrolled

Breast Cancer Organoids

NCT03703427 2018-10-12

Capecitabine Versus Vinorelbine in High Risk Breast Cancer With Pathologic Residual Tumors After Preoperative Chemotherapy

Pathologic Residual Cancer Cells

NCT03656393 2018-09-04

RCTACSCNSCLC

48 enrolled

NSCLC

NCT03188159 2018-03-29

Vinorelbine in Relapsed Platinum Resistant or Refractory C5 High Grade Serous, Endometrioid, or Undifferentiated Primary Peritoneum, Fallopian Tube or Ovarian Cancer

36 enrolled

Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT03423849 2018-02-06

The Maintenance Regimen and Revised Regimen for Advanced Breast Cancer Survivors After First-line Salvage Therapy

Phase 2/3 Unknown

Breast Neoplasms

NCT03359694 2017-12-02

Mutation Scores and Differential Protein Evaluating Efficacy in Adjuvant Chemotherapy in HER2(-) Luminal B Breast Cancer

300 enrolled

Breast Neoplasms, Genetic Predisposition to Disease

NCT02489409 2017-07-17

Recombinant Human Endostatin (EndostarTM) Injection in Treatment of Recurrent Metastatic Breast Cancer

120 enrolled

Breast Neoplasms

NCT02144194 2017-02-09

TNM

65 enrolled

Breast Neoplasms

NCT03006614 2017-01-16

PERS

320 enrolled

Breast Neoplasms

NCT02579564 2016-10-21

Systemic Chemotherapy Combined With Recombinant Human Adenovirus Type 5 and Endostatin Injections for Treatment Malignant Hydrothorax in NSCLC Patients

134 enrolled

Carcinoma, Non-Small-Cell Lung

NCT01683175 2016-10-20

Erlotinib in Post Radical Operation NSCLC Patients With EGFR Mutation

94 enrolled

Carcinoma, Non-Small-Cell Lung

NCT02897986 2016-09-13

PROVIN

Phase 1 Unknown

54 enrolled

Tumor-Agnostic

Neoplasms

NCT02665702 2016-01-28

Endostar Combined With NVB and DDP Second-line Treatment of Advanced Esophageal Squamous Cell Carcinomas

76 enrolled

Gastrointestinal

Esophageal Squamous Cell Carcinoma

NCT02544243 2015-09-09

Vinorelbine/Gemcitabine Versus Vinorelbine/Cisplatin in Metastatic Breast Cancer

Breast Neoplasms

NCT02319577 2014-12-18

GEfitinib Plus viNOrelbine in Advanced EGFR Mutated NSCLC. GENOA Trial

80 enrolled

Carcinoma, Non-Small-Cell Lung

NCT02281708 2014-11-03

Multicenter Randomized Controlled Trial Adjuvant Chemotherapy vs Observation in pStage Ib Lung Adenocarcinoma

1,012 enrolled

Lung Neoplasms, Recurrence

NCT02223611 2014-08-22

S1VSNP

100 enrolled

Non-small Cell Lung Cancer Stage Ⅱ

NCT02188615 2014-07-11

NACRFMIE